Expansion of the APAC CMO Business Driven by OLIC’s New Injectable Drug Manufacturing Facility
First written in FY2017. 6 of 13 entries say "Advanced", first in FY2018. Latest entry: 2026-08-06.
1 other company's latest entry also says "Restated".
- FY2025-H1AdvancedAnnual report
「In the "Global CMO" business, OLIC's contract manufacturing revenue increased.」
Describes growth in contract manufacturing revenue during the current interim consolidated accounting period in the global CMO business centered on OLIC. - FY2024-Q2AdvancedAnnual report
「Contract manufacturing of pharmaceuticals 3,348 3,742」
Revenue from contract manufacturing of pharmaceuticals increased from ¥3,348 million in the previous year to ¥3,742 million, indicating improved performance in the contract manufacturing business. - FY2024-Q1Modest recovery in contract manufacturing revenueAnnual report
「Contract manufacturing of pharmaceuticals 1,689 1,707」
Revenue from contract manufacturing of pharmaceuticals increased modestly from ¥1,689 million in the same period of the previous year to ¥1,707 million, a change from the previous year's reported revenue decline. - FY2023-Q3WorsenedAnnual report
「Contract manufacturing of pharmaceuticals 5,662 4,902」
Revenue from contract manufacturing of pharmaceuticals declined from ¥5,662 million in the same period of the previous year to ¥4,902 million, marking a continued decline in contract manufacturing revenue. - FY2023-Q2WorsenedAnnual report
「Contract manufacturing of pharmaceuticals 3,808 3,348」
Revenue from contract manufacturing of pharmaceuticals declined from ¥3,808 million in the same period of the previous year to ¥3,348 million, indicating a decline in the performance of the contract manufacturing business. - FY2022AdvancedAnnual report
「As a result, net sales for the consolidated fiscal year were ¥35,426 million, up 4.2% year on year. In terms of profit, operating profit was ¥3,777 million, up 12.8%, ordinary profit was ¥3,725 million, up 14.6%, and profit attributable to owners of the parent was ¥2,696 million, up 10.9%, reflecting steady sales of products in the women’s healthcare field and growth in contract revenue at OLIC.」
Describes specific business progress in the CMO business centered on OLIC, with growth in contract manufacturing revenue. - FY2021RestatedAnnual report
「With our subsidiary OLIC (Thailand) Limited as the core of the business, we will achieve growth as a CMO in Asia while expanding our manufacturing and marketing business in China and ASEAN.」
Continues the policy of growing the Asian CMO business centered on OLIC and expanding manufacturing and marketing operations in China and ASEAN. - FY2020RaisedAnnual report
「⑥ Asia: With our subsidiary OLIC as the core of the business, we will achieve growth as a CMO in Asia while expanding our manufacturing and marketing business in China and ASEAN.」
The scope of expansion has broadened beyond the APAC CMO business centered on OLIC to include manufacturing and marketing operations in China and ASEAN. - FY2018AdvancedAnnual report
「We will expand our global CMO business through OLIC's injectable manufacturing facility, which began operations in January 2018, and aim to become a "Sustainable Leading CMO in APAC."」
OLIC's new injectable manufacturing facility has progressed from a future launch plan to an operating facility that began operations in January 2018. - FY2017First statedAnnual report
「We will launch OLIC's new injectable manufacturing facility, expand our global CMO business with new customers and aim to become a "Sustainable Leading CMO in APAC."」
For the first time, specifically describes the policy of using OLIC's new injectable manufacturing facility to pursue a sustainably leading CMO business in APAC.